TITLE

FUROSEMIDE AND PLASMA RENIN ACTIVITY IN ESSENTIAL HYPERTENSION

AUTHOR(S)
Hutcheon, Duncan E.; Sandhu, Randhir
PUB. DATE
October 1976
SOURCE
Angiology;Oct1976, Vol. 27 Issue 10, p579
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Changes in arterial blood pressure, renal electrolyte excretion, and plasma renin activity in response to repeated doses of furosemide were measured in 12 patients with essential hypertension admitted to the medical service for electrolyte balance studies. Eighty and 120 mg/day furosemide in divided doses for 5 to 10 days produced a prompt increase in renal sodium excretion. Urinary Na/K concentration ratios, which were elevated during peak natriuresis, returned to control levels following the initial diuretic response. In 2 patients with high initial levels of plasma renin activity, arterial blood pressure was not reduced by furosemide, and more potent antihypertensive agents were required to control the blood pressure. In the remaining patients, furosemide produced a significant decrease in systolic and diastolic blood pressure. There was a general upward shift of plasma renin levels in terms of 24-hour renal sodium excretion in those who demonstrated an antihypertensive response to the drug. However, the average increase in plasma renin activity after repeated doses of furosemide was not statistically significant and no correlation was demonstrated between the level of plasma renin activity after furosemide and the blood pressure lowering effect of the drug.
ACCESSION #
16352582

 

Related Articles

  • LONG-TERM EFFECTS OF FUROSEMIDE AND HYDROCHLOROTHIAZIDE IN PATIENTS WITH ESSENTIAL HYPERTENSION. Finnerty, Frank A.; Maxwell, Morton H.; Lunn, John; Moser, Marvin // Angiology;Feb1977, Vol. 28 Issue 2, p125 

    In a double-blind study the long-term effects of diuretics in uncomplicated mild and moderate essential hypertension were investigated. A total of 52 outpatients completed 24 months of treatment with either furosemide at a dose of 40 mg twice daily (26 patients) or hydrochlorothiazide at a dose...

  • CURRENT DRUG THERAPY IN HYPERTENSION. Brest, Albert N.; Moyer, John H. // Angiology;Feb1963, Vol. 14 Issue 2, p64 

    At present, diastolic hypertension can be controlled in the overwhelming majority of instances. However a double- or triple-drug regimen may be required in patients with moderate or severe diastolic blood pressure elevation.

  • Hypertension and peripheral arterial disease. Olin, Jeffrey W. // Vascular Medicine;2005, Vol. 10 Issue 3, p241 

    Studies the treatment of hypertension in patients with peripheral arterial disease. Recognition and prevalence of peripheral arterial disease; Cardiovascular events in hypertension and peripheral arterial disease; Drug therapy to treat hypertension in peripheral arterial disease; Beneficial...

  • Drug Treatment of Pulmonary Arterial Hypertension: Current and Future Agents. Hoeper, Marius M. // Drugs;2005, Vol. 65 Issue 10, p1337 

    During the last decade we have witnessed substantial improvements in the therapeutic options for pulmonary arterial hypertension (PAH), including true innovations targeting some of the mechanisms involved in the pathogenesis of this devastating disease. Intravenous epoprostenol was the first...

  • Pharmacokinetics of Olmesartan Medoxomil plus Hydrochlorothiazide Combination in Healthy Subjects. Kreutz, Reinhold; Bolbrinker, Juliane; Huber, Matthias // Clinical Drug Investigation;2006, Vol. 26 Issue 1, p29 

    BACKGROUND: Hypertension treatment guidelines recommend combination therapy with diuretics and other antihypertensive agents, including angiotensin II type 1 (AT1) receptor antagonists. This trial investigated the possibility of pharmacokinetic interactions between the AT1 receptor antagonist...

  • Prostaglandins and Hypertension. Barger, A. Clifford // Angiology;Apr1978, Vol. 29 Issue 4, p320 

    Evidence is presented demonstrating the role of prostaglandins in salt metabolism and on peripheral vasodilation. A number of animal studies and observations in buman bypertensive subjects suggest that the prostaglandin system plays a role in the pathogenesis of hypertension. The most striking...

  • C. Hypertension and Systemic Disease.  // Kidney;Jul/Aug2004, Vol. 13 Issue 4, p171 

    Presents summaries of research on hypertension and systemic disease. Significance of the increased levels of circulating angiogenic factors to predict preeclampsia; Effects of urinary ammonium and pH on the risk of uric acid precipitation; Importance of high-dose chemotherapy with stem cell...

  • Refractory Hypertension in an Otherwise Healthy Adolescent. Davis, Charles A.; Kallen, Ronald J.; Goldberg, Alan D. // Clinical Pediatrics;Sep1981, Vol. 20 Issue 9, p587 

    Severe hypertension, for which no cause could be found, developed in an adolescent female. The patient's blood pressure was refractory to intensive pharmacologic intervention. After 1½ years of medical management, the patient's intra-arterial blood pressures were found to he in the...

  • Advantages and Disadvantages of Beta- Adrenergic Blocking Drugs in Hypertension. O'Brien, Eoin T. // Angiology;Apr1978, Vol. 29 Issue 4, p332 

    This paper reviews the role of beta-adrenergic blocking drugs in the treatment of hypertension. A significant proportion of patients presenting with mild or moderate hypertension will respond to general measures and do not require specific drug therapy. Of the remaining patients, some will...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics